News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Let's take a look at what these …
Sharemaestro market context Trend signal active 52 weeks +30.6% · Next-week setup negative 30.7%Wedbush has increased its price target for Stoke Therapeutics (NASDAQ: STOK) to $40 from $38, while reiterating an Outperform rating on the stock. This adjustment follows recent company news, including the Q2 2026 earnings call and updates on their Phase 3 study for Dravet …
The Real Brokerage Inc. (REAX) has set an August 18, 2026, 5:00 p.m. New York City time deadline for RE/MAX Holdings (REMAX) Class A stockholders to elect their form of consideration in the pending acquisition. Stockholders who do not make a valid election will …
Stoke Therapeutics, Inc. reported its Q2 2026 results, showing a decrease in revenue to $9.3M from $13.8M in Q2 2025, and a widened net loss of $(61.6M) with a diluted EPS of $(0.93). The company highlighted clinical progress for zorevunersen with Phase 3 trial …
Earnings Call Insights: Stoke Therapeutics (STOK) Q2 2026 MANAGEMENT VIEW * "Starting with our Phase III EMPEROR study, the recent completion of enrollment of 162 patients in just 10 months speaks to the awareness and enthusiasm of zorevunersen" (CEO & Director Ian Smith). "We …
This article analyzes Stoke Therapeutics Inc. (STOK) using AI models to provide trading strategies for different risk profiles and holding periods. It highlights divergent sentiment, support/resistance levels, and a favorable risk-reward setup for the stock. The analysis includes position trading, momentum breakout, and risk …
Stoke Therapeutics (NASDAQ:STOK) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $43.00, despite recently missing earnings per share estimates while exceeding revenue forecasts. Insider sales by two executives under pre-arranged plans have been noted, though insiders …
Oneok Inc. (OKE) reported strong Q2 earnings of $1.53 per share, surpassing the Zacks Consensus Estimate of $1.39 and showing a significant increase from $1.34 a year ago. The company also exceeded revenue expectations, posting $12.05 billion against an estimated $10.66 billion. While Oneok's …
GREENWICH, Conn., August 03, 2026--(BUSINESS WIRE)--Interactive Brokers Group, Inc. (Nasdaq: IBKR) an automated global electronic broker, today reported its Electronic Brokerage monthly performance metrics for July. Brokerage highlights for the month included: 4.426 million Daily Average Revenue Trades (DARTs)1, 27% higher than prior year …
Sharemaestro market context Trend signal active 52 weeks +30.6% · Next-week setup negative 30.7%Ariel Investments, an investment management company, released its "Appreciation Fund" Q2 2026 investor letter. A copy of the letter can be downloaded here. The fund gained 13.71% in the second quarter of 2026, slightly outperforming the Russell Midcap Value Index's 13.40% return but trailing …
ONEOK has revised its 2026 forecast upwards, attributing this positive adjustment to increased natural gas liquids (NGL) volumes. This improvement in NGL volumes also contributed to a boost in the company's quarterly profit. The article also notes recent analyst rating changes and price target …
Stoke Therapeutics reported a quarterly loss of $0.93 per share, missing analyst estimates by $0.13, despite revenue of $9.32 million exceeding expectations. The company remains unprofitable, but its shares rose by $0.70 to $29.56 following the announcement. Analysts maintain a "Moderate Buy" consensus with …
Oneok Inc. (OKE) reported $12.05 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 52.8%. EPS of $1.53 for the same period compares to $1.34 a year ago. The reported revenue represents a surprise of +13.03% over the Zacks …
ONEOK (OKE) reported stronger-than-expected Q2 2026 earnings with revenue reaching $12.0 billion and net income attributable to common shareholders increasing to $966 million. Diluted EPS was $1.53, and operating cash flow stood at $2.1 billion. The article also details significant hedge fund activity, congressional …
ONEOK, Inc. reported strong second-quarter 2026 results with a 13% increase in net income to $967 million and a 7% increase in adjusted EBITDA to $2.12 billion. The company also raised its 2026 financial guidance, reflecting continued strong business performance and strategic growth projects. …
Stoke Therapeutics reported a significant financial downturn in H1 2026, swinging to a net loss of $111.6 million compared to a net income of $89.4 million in H1 2025, primarily due to a sharp decline in revenue from $172.4 million to $15.6 million. This …
Stoke Therapeutics announced the completion of enrollment for its Phase 3 EMPEROR study of zorevunersen in Dravet syndrome, with 162 patients enrolled and a data readout expected in Q3 2027. The company is preparing for a rolling U.S. NDA submission to begin in Q1 …
Stoke Therapeutics reported a wider-than-expected Q2 2026 loss but significantly beat revenue forecasts, driven by the advancement of its Dravet syndrome drug, zorevunersen, towards a potential U.S. launch in early 2028. The company's Phase III EMPEROR study has exceeded enrollment targets with no patient …
ONEOK (OKE) shares fell 3.1% ahead of its Q2 2026 earnings release, influenced by a general softening in energy sector sentiment and a recent analyst downgrade citing concerns about Bakken growth. The decline was also exacerbated by a sharp drop in oil prices due …
ONEOK Inc. (OKE) shares dropped 1.67% on Monday, closing at $88.24, despite a strong overall market performance where the S&P 500 and Dow Jones Industrial Average both saw significant gains. This decline leaves ONEOK Inc. 8.15% below its 52-week high. The article highlights the …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Houlihan Lokey (NYSE:HLI) has been recognized as the leading M&A adviser by deal volume in North America for the first half of 2026. The ranking …
ONEOK Inc. is set to report second-quarter earnings, with analysts watching whether strong Permian Basin volumes can counteract concerns about its Bakken operations. While analysts expect increased earnings per share and revenue, some express caution due to investor doubts about sustained EBITDA growth and …
Stock exchange market chart data on LED display by Golden House Images via Adobe Stock Greenwich, Connecticut-based Interactive Brokers Group, Inc. (IBKR) operates as an automated electronic broker. Valued at $149.3 billion by market cap, the company specializes in executing and clearing trades in …
Sharemaestro market context Trend signal active 52 weeks +30.6% · Next-week setup negative 30.7%Seaport Global has increased its price target for ONEOK (OKE) to $100 from $95, while reiterating a "Buy" rating on the stock. This adjustment reflects an updated outlook from the firm regarding the natural gas distributor. The article also notes other recent analyst rating …
Edgestream Partners L.P. significantly reduced its stake in ONEOK, Inc. by 70.9% in the first quarter, selling 54,730 shares while retaining 22,436 shares valued at $2.03 million. Despite this, institutional investors collectively hold 69.13% of ONEOK's stock. The company recently declared a quarterly dividend …
Sharemaestro market context Trend signal active 52 weeks +32.3%This article first appeared on GuruFocus. Assessing the Sustainability and Growth of ONEOK Inc's Upcoming Dividend Payment ONEOK Inc (NYSE:OKE) recently announced a total dividend of $1.07 per share, with the ex-dividend date set for 2026-08-03. This includes a $1.07 per share cash dividend …
ONEOK, Inc. (OKE) has approximately 6,360 employees worldwide as of March 2026, marking a 5.2% growth since 2023 but a 0.2% decline year-over-year in 2026. The company, headquartered in Tulsa, Oklahoma, actively seeks new hires but has seen a significant 42.6% drop in job …
SunCoke Energy reported a significant increase in Q2 2026 consolidated adjusted EBITDA, reaching $69.6 million, primarily due to the Phoenix acquisition and strong terminal volumes. The company raised its full-year EBITDA guidance to $250-$265 million and declared a $0.12 quarterly dividend. Both domestic coke …
Janus Henderson Group PLC increased its stake in Stoke Therapeutics (NASDAQ:STOK) by 11.2% in the first quarter, now owning over 1.6 million shares valued at approximately $52.5 million. Despite a quarterly loss, analyst sentiment remains positive with a "Moderate Buy" consensus rating and an …
Search by ticker symbol or company name and select a result to open its chart.